CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial

CorMedix Inc.

CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.
List price (WAC) set at $249.99 per 3mL vial; company committed to reduce price if Part B reimbursement is granted.
Reiterates inpatient launch target of April 15, 2024; outpatient launch target of July 1, 2024, contingent on CMS TDAPA approval.
Company will notify CMS to adjust inpatient NTAP reimbursement now that a WAC price is established.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.